1. Home
  2. FRBA vs DMAC Comparison

FRBA vs DMAC Comparison

Compare FRBA & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bank

FRBA

First Bank

N/A

Current Price

$19.64

Market Cap

508.6M

Sector

Finance

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

N/A

Current Price

$9.04

Market Cap

501.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRBA
DMAC
Founded
2007
2000
Country
United States
United States
Employees
336
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.6M
501.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FRBA
DMAC
Price
$19.64
$9.04
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
★ $21.67
$15.50
AVG Volume (30 Days)
113.9K
★ 198.3K
Earning Date
10-22-2026
11-12-2026
Dividend Yield
★ 2.43%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $500,000.00
Revenue This Year
$2.61
N/A
Revenue Next Year
$5.91
N/A
P/E Ratio
$9.71
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.41
$5.25
52 Week High
$21.29
$11.00

Technical Indicators

Market Signals
Indicator
FRBA
DMAC
Relative Strength Index (RSI) 60.96 49.91
Support Level $17.04 $5.86
Resistance Level $21.29 $11.00
Average True Range (ATR) 0.59 0.76
MACD -0.04 -0.09
Stochastic Oscillator 24.53 29.41

Price Performance

Historical Comparison
FRBA
DMAC

About FRBA First Bank

First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: